Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Revenue (2016 - 2025)

Historic Revenue for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $169.1 million.

  • Amicus Therapeutics' Revenue rose 1946.34% to $169.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $598.7 million, marking a year-over-year increase of 2127.59%. This contributed to the annual value of $528.3 million for FY2024, which is 3228.67% up from last year.
  • According to the latest figures from Q3 2025, Amicus Therapeutics' Revenue is $169.1 million, which was up 1946.34% from $154.7 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Revenue high stood at $169.1 million for Q3 2025, and its period low was $66.4 million during Q1 2021.
  • For the 5-year period, Amicus Therapeutics' Revenue averaged around $105.9 million, with its median value being $94.5 million (2023).
  • As far as peak fluctuations go, Amicus Therapeutics' Revenue surged by 269.78% in 2022, and later soared by 3673.01% in 2024.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Revenue stood at $82.2 million in 2021, then rose by 7.23% to $88.1 million in 2022, then skyrocketed by 30.63% to $115.1 million in 2023, then soared by 30.09% to $149.7 million in 2024, then rose by 12.93% to $169.1 million in 2025.
  • Its last three reported values are $169.1 million in Q3 2025, $154.7 million for Q2 2025, and $125.2 million during Q1 2025.